4D Molecular Therapeutics, Inc. (FDMT) stock
Close on Nov 11, 2026Market cap $937.62MP/E –Yield –
4D Molecular Therapeutics, Inc. grew revenue 278712.1% to $92.01M over the twelve months to Jun 30, 2026. Free cash flow was -$109.62M. At the latest close the market valued the company at $937.62M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $937.62M
- P/E ratio
- –
- Price to sales
- 10.19
- Price to book
- 2.30
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $92.01M
- Net income
- -$179.18M
- EPS, diluted
- -$2.76
- Free cash flow
- -$109.62M
- Book value per share
- $5.80
- Diluted shares
- 70M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $12.46
- Open
- $12.48
- Day's range
- $12.38 – $13.03
- Volume
- 837,177
- Average volume (20 days)
- 1,004,945
- Index membership
- Russell 2000 (since Mar 2021), Russell 3000 (since May 2021)
- Beta (5 years)
- 1.35
- 52-week range
- $6.96 – $16.93
- RSI (14 days)
- 53.6
- Volatility (1 year)
- 77.0%
- Relative volume
- 0.90×
- WACC
- 11.5%
On 1 of our idea list: Most shorted (a warning list)
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | FDMT | S&P 500 | Difference | FDMT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.6% | -2.4% | −0.1 pts | ||
| 3 months | +13.3% | -1.2% | +14.4 pts | ||
| Year to date | +73.2% | +12.3% | +60.9 pts | ||
| 1 year | +20.3% | +12.4% | +7.8 pts | ||
| 3 years | +17.6% | +78.8% | −61.3 pts | +5.5% | +21.4% |
| 5 years | -47.6% | +75.2% | −122.7 pts | -12.1% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases 4D Molecular Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About 4D Molecular Therapeutics
Biological Products, (No Diagnostic Substances)
4D Molecular Therapeutics is a clinical-stage biotechnology company that develops disease-targeted genetic medicines. The company engineers therapies using its proprietary Therapeutic Vector Evolution platform, which creates customized adeno-associated virus vectors. Its development pipeline centers on clinical-stage therapeutic candidates for retinal and lung conditions. The lead candidate, 4D-150, targets retinal vascular diseases by delivering biologics that inhibit vascular endothelial growth factors. Additional pipeline programs include 4D-175, 4D-710, and 4D-725. The company works with collaboration partners, including Otsuka Pharmaceutical and the Cystic Fibrosis Foundation, to develop treatments for patients.
Company profile, executives and history4D Molecular Therapeutics stock: common questions
What is 4D Molecular Therapeutics's stock price?
FDMT closed at $12.99 on Nov 11, 2026, up 4.25% on the day. Over the past 52 weeks it traded between $6.96 and $16.93.
What is 4D Molecular Therapeutics's market cap?
4D Molecular Therapeutics was worth $937.62M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is FDMT's P/E ratio?
4D Molecular Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$2.76), so it has no meaningful P/E ratio.
How much revenue does 4D Molecular Therapeutics make?
4D Molecular Therapeutics reported revenue of $92.01M for the twelve months to Jun 30, 2026, up 278712.1% from a year earlier.
Does 4D Molecular Therapeutics pay a dividend?
No. 4D Molecular Therapeutics has not paid a cash dividend over the last twelve months.
When does 4D Molecular Therapeutics report earnings next?
4D Molecular Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has FDMT stock performed over the past year?
Including dividends, FDMT returned +20.3% over the past year, against +12.4% for the S&P 500.
How many FDMT shares are sold short?
11M shares were sold short at the latest FINRA report, 15.42% of the float, or 10.4 days of average trading volume.
Who are 4D Molecular Therapeutics's competitors?
Companies most similar to 4D Molecular Therapeutics by business, industry and size include BEAM, RGNX, SGMOQ, MAZE, KYMR.
See a number that looks wrong?